Significantly, GM101+SBHA- or GM101+MS-275-treated tumors exhibited significantly lower levels of major ECM components (collagen I and fibronectin) in comparison to the tumors treated with any of the monotherapy regimens (P < 0.05 or P < 0.001), suggesting that HDACi can enhance the ECM degrading property of GM101 in tumor tissues. This evidence concerns the gene FN1 and neoplasm.